6,678 trials
Pulmonary Disease, Chronic Obstructive
Primary: Number of Participants With Adverse Events (AE), Serious Adverse Events (SAE) and Adverse Events of Special Interest (AESIs) — 35; 1; 0 Participants
Tetraplegia · Hypothermia · Mild Cognitive Impairment
Primary: Change in Core Body Temperature — -0.24; -0.97; NA; 0.79 °C — p=<0.001
Major Depressive Disorder
Primary: Change in Cognitive Control Circuit Function Z-score — 0.350; 0.441; 0.105; 0.324 Z-score — p=0.020
Obstructive Sleep Apnea
Primary: Time to Discharge From Operating Room — 13.0; 13.5 Minutes
Human Papillomavirus Infection
Primary: HPV Incidence Rates, Expressed as Incident Infections/1000 Infection-months at Risk. These Were Calculated Separately for Females and Males Across the Four Vaccine…
Cystic Fibrosis-related Diabetes
Primary: Time in Target — 67; 68 percentage of time in range — p=<0.01
Hypertension · Genetics Hypertension
Primary: Systolic /Diastolic Supine Morning Liberal Salt Automated Blood Pressure — 144.2; 148.5; 86.0; 91.4 mm hg — p=0.823
Microbial Colonization
Primary: Phylum Level Mean Proportional Relative Abundance — 0.167; 0.0271; 0.686; 0.0391 % gram positive (+) for phylum
Drug-Drug Interaction · HIV Infection
Primary: AUC0-42day in 3-dose Study — 4.47; 14.9; 49.7; 14.6 hr.ug/mL
Asthma and/or Exercise Induced Bronchoconstriction · Ozone Air Pollution
Primary: Measured Before and 30 Minutes After Exercise in Each 1 Day Condition — 6.98; 5.96; -1.38; -.35 litres
Dry Eye
Primary: Tear Lipid Layer Thickness — 0.72; -7.58; 2.06; 1.41 nm
HIV Infection · Vaginal Atrophy · Menopause
Primary: Change in Most Bothersome Symptom (MBS) of Vaginal Atrophy — 0; 1; 8; 4 Participants
Hypogonadism · Hypogonadism, Male · Hypogonadotropic Hypogonadism
Primary: Change From Baseline in 24-Hour Average Systolic Ambulatory Blood Pressure to End of Study (EOS) — 2.77; 2.78; 2.15 millimeters of mercury (mmHg)
Psoriasis
Primary: Percentage of Participants With a Scalp-specific Physician Global Assessment Score of 0 or 1 (Ss-PGA 0/1) at Week 16 — 48.5; 13.7; 50.0; 12.8 Percentage of responders…
Distribution of Ropivacaine in Erector Spinae Plane Block
Primary: Area of Dermatomal Sensory Loss at 20 Min — 68.8; 167.5 cm^2